HIGHLIGHTS OF PRESCRIBING INFORMATION forERBITUX. …

1. HIGHLIGHTS OF PRESCRIBING INFORMATION ------------------------DOSAGE AND ADMINISTRATION---------------------- These HIGHLIGHTS do not include all the INFORMATION needed to use Premedicate with an H1 receptor antagonist. ( ). ERBITUX safely and effectively. See full PRESCRIBING INFORMATION 2. for ERBITUX. Administer 400 mg/m initial dose as a 120-minute intravenous 2.. ERBITUX ( cetuximab ) injection, for intravenous use infusion followed by 250 mg/m weekly infused over 60 minutes. ( , , ). Initial Approval: 2004. Initiate ERBITUX one week prior to initiation of radiation therapy. WARNING: INFUSION REACTIONS and CARDIOPULMONARY Complete ERBITUX administration 1 hour prior to irinotecan, ARREST platinum-based therapy with fluorouracil or FOLFIRI. ( , ). See full PRESCRIBING INFORMATION for complete boxed warning. ERBITUX can cause serious and fatal infusion reactions. ----------------------DOSAGE FORMS AND STRENGTHS-------------------- ( , 6) Immediately interrupt and permanently discontinue Injection: 100 mg/50 mL (2 mg/mL) or 200 mg/100 mL (2 mg/mL).

patients with squamous cell carcinoma of the head and neck receivingERBITUXwithradiation therapy orwith a cetuximab product with platinum-based therapy and fluorouracil. Monitor serum electrolytes, including serum magnesium, potassium, and calcium, during and after ERBITUXadministration. (5.2, 5.6)

Tags:

  Cells, Carcinoma, Squamous, Squamous cell carcinoma, Cetuximab

Information

Related search queries